AAPL341.07+5.15 (+1.53%) ▲|ABBV264.34-0.78 (-0.29%) ▼|ABT101.29+0.22 (+0.22%) ▲|ACN176.11-1.30 (-0.73%) ▼|ADBE235.47-3.46 (-1.45%) ▼|AMAT485.00+10.75 (+2.27%) ▲|AMD630.63+1.37 (+0.22%) ▲|AMGN414.61+8.57 (+2.11%) ▲|AMT169.03+1.77 (+1.06%) ▲|AMZN249.67+0.29 (+0.12%) ▲|AVGO352.81+2.45 (+0.70%) ▲|AXP308.89+3.23 (+1.06%) ▲|BA198.07+1.27 (+0.65%) ▲|BAC56.70+0.67 (+1.20%) ▲|BKNG163.95+6.54 (+4.15%) ▲|BLK1,086.31+12.86 (+1.20%) ▲|BMY62.86+1.36 (+2.21%) ▲|BNY150.15-0.04 (-0.03%) ▼|BRK-B505.48+0.30 (+0.06%) ▲|C134.28+2.18 (+1.65%) ▲|CAT821.58+16.33 (+2.03%) ▲|CL86.06+0.74 (+0.87%) ▲|CMCSA21.91-0.22 (-0.99%) ▼|COF200.20+3.59 (+1.83%) ▲|COP127.30-2.04 (-1.58%) ▼|COST922.77+26.29 (+2.93%) ▲|CRM234.02-4.20 (-1.76%) ▼|CSCO106.70-0.27 (-0.25%) ▼|CVS89.13+4.08 (+4.80%) ▲|CVX204.45-1.20 (-0.58%) ▼|DE690.46-4.48 (-0.64%) ▼|DHR224.49+0.72 (+0.32%) ▲|DIS106.15+0.59 (+0.56%) ▲|DUK113.35+0.12 (+0.11%) ▲|EMR158.23+2.09 (+1.34%) ▲|FDX285.85+6.31 (+2.26%) ▲|GD336.72+0.43 (+0.13%) ▲|GE327.09+7.31 (+2.29%) ▲|GEV957.63+2.59 (+0.27%) ▲|GILD150.93+1.24 (+0.83%) ▲|GM82.63+2.06 (+2.56%) ▲|GOOG341.08+2.07 (+0.61%) ▲|GOOGL343.92+1.56 (+0.46%) ▲|GS935.45+12.16 (+1.32%) ▲|HD293.20+1.02 (+0.35%) ▲|HON212.55+0.76 (+0.36%) ▲|IBM225.51-1.55 (-0.68%) ▼|INTC123.00-4.39 (-3.45%) ▼|INTU275.79-1.34 (-0.48%) ▼|ISRG405.18+5.66 (+1.42%) ▲|JNJ271.22+0.54 (+0.20%) ▲|JPM343.06+4.50 (+1.33%) ▲|KO87.81-0.29 (-0.33%) ▼|LIN469.89+1.75 (+0.37%) ▲|LLY1,183.46+1.57 (+0.13%) ▲|LMT519.56-4.14 (-0.79%) ▼|LOW189.28+0.79 (+0.42%) ▲|LRCX315.21+8.05 (+2.62%) ▲|MA567.65+1.57 (+0.28%) ▲|MCD236.50-0.52 (-0.22%) ▼|MDLZ60.25-0.61 (-1.00%) ▼|MDT88.64+0.85 (+0.97%) ▲|META751.66-25.93 (-3.33%) ▼|MMM169.55+2.03 (+1.21%) ▲|MO68.82-0.06 (-0.09%) ▼|MRK148.78+0.80 (+0.54%) ▲|MS196.31-0.01 (-0.01%) ▼|MSFT516.17+18.24 (+3.66%) ▲|MU1,082.28+1.75 (+0.16%) ▲|NEE76.08+0.46 (+0.61%) ▲|NFLX71.15-0.58 (-0.80%) ▼|NKE35.75-0.24 (-0.67%) ▼|NOW135.62-2.16 (-1.57%) ▼|NVDA225.07+0.49 (+0.22%) ▲|ORCL137.10-2.44 (-1.75%) ▼|PEP128.63+0.48 (+0.37%) ▲|PFE28.67+0.26 (+0.92%) ▲|PG146.23+0.55 (+0.38%) ▲|PLTR189.67-2.92 (-1.52%) ▼|PM190.48-1.02 (-0.53%) ▼|QCOM201.97+7.71 (+3.97%) ▲|RTX189.40+0.79 (+0.42%) ▲|SBUX94.86+1.21 (+1.29%) ▲|SCHW99.03-0.46 (-0.46%) ▼|SO82.88-0.01 (-0.01%) ▼|SPG204.82+0.12 (+0.06%) ▲|T25.38-0.07 (-0.28%) ▼|TMO675.00-3.39 (-0.50%) ▼|TMUS165.43+0.08 (+0.05%) ▲|TSLA372.11-5.83 (-1.54%) ▼|TXN278.07+7.42 (+2.74%) ▲|UBER69.62+0.40 (+0.58%) ▲|UNH376.59+1.58 (+0.42%) ▲|UNP273.79-0.28 (-0.10%) ▼|UPS93.96+1.91 (+2.08%) ▲|USB59.33+0.93 (+1.59%) ▲|V367.38-0.60 (-0.16%) ▼|VZ47.08-0.24 (-0.51%) ▼|WFC82.97+0.79 (+0.96%) ▲|WMT107.98+0.39 (+0.36%) ▲|XOM160.59-1.55 (-0.96%) ▼|AAPL341.07+5.15 (+1.53%) ▲|ABBV264.34-0.78 (-0.29%) ▼|ABT101.29+0.22 (+0.22%) ▲|ACN176.11-1.30 (-0.73%) ▼|ADBE235.47-3.46 (-1.45%) ▼|AMAT485.00+10.75 (+2.27%) ▲|AMD630.63+1.37 (+0.22%) ▲|AMGN414.61+8.57 (+2.11%) ▲|AMT169.03+1.77 (+1.06%) ▲|AMZN249.67+0.29 (+0.12%) ▲|AVGO352.81+2.45 (+0.70%) ▲|AXP308.89+3.23 (+1.06%) ▲|BA198.07+1.27 (+0.65%) ▲|BAC56.70+0.67 (+1.20%) ▲|BKNG163.95+6.54 (+4.15%) ▲|BLK1,086.31+12.86 (+1.20%) ▲|BMY62.86+1.36 (+2.21%) ▲|BNY150.15-0.04 (-0.03%) ▼|BRK-B505.48+0.30 (+0.06%) ▲|C134.28+2.18 (+1.65%) ▲|CAT821.58+16.33 (+2.03%) ▲|CL86.06+0.74 (+0.87%) ▲|CMCSA21.91-0.22 (-0.99%) ▼|COF200.20+3.59 (+1.83%) ▲|COP127.30-2.04 (-1.58%) ▼|COST922.77+26.29 (+2.93%) ▲|CRM234.02-4.20 (-1.76%) ▼|CSCO106.70-0.27 (-0.25%) ▼|CVS89.13+4.08 (+4.80%) ▲|CVX204.45-1.20 (-0.58%) ▼|DE690.46-4.48 (-0.64%) ▼|DHR224.49+0.72 (+0.32%) ▲|DIS106.15+0.59 (+0.56%) ▲|DUK113.35+0.12 (+0.11%) ▲|EMR158.23+2.09 (+1.34%) ▲|FDX285.85+6.31 (+2.26%) ▲|GD336.72+0.43 (+0.13%) ▲|GE327.09+7.31 (+2.29%) ▲|GEV957.63+2.59 (+0.27%) ▲|GILD150.93+1.24 (+0.83%) ▲|GM82.63+2.06 (+2.56%) ▲|GOOG341.08+2.07 (+0.61%) ▲|GOOGL343.92+1.56 (+0.46%) ▲|GS935.45+12.16 (+1.32%) ▲|HD293.20+1.02 (+0.35%) ▲|HON212.55+0.76 (+0.36%) ▲|IBM225.51-1.55 (-0.68%) ▼|INTC123.00-4.39 (-3.45%) ▼|INTU275.79-1.34 (-0.48%) ▼|ISRG405.18+5.66 (+1.42%) ▲|JNJ271.22+0.54 (+0.20%) ▲|JPM343.06+4.50 (+1.33%) ▲|KO87.81-0.29 (-0.33%) ▼|LIN469.89+1.75 (+0.37%) ▲|LLY1,183.46+1.57 (+0.13%) ▲|LMT519.56-4.14 (-0.79%) ▼|LOW189.28+0.79 (+0.42%) ▲|LRCX315.21+8.05 (+2.62%) ▲|MA567.65+1.57 (+0.28%) ▲|MCD236.50-0.52 (-0.22%) ▼|MDLZ60.25-0.61 (-1.00%) ▼|MDT88.64+0.85 (+0.97%) ▲|META751.66-25.93 (-3.33%) ▼|MMM169.55+2.03 (+1.21%) ▲|MO68.82-0.06 (-0.09%) ▼|MRK148.78+0.80 (+0.54%) ▲|MS196.31-0.01 (-0.01%) ▼|MSFT516.17+18.24 (+3.66%) ▲|MU1,082.28+1.75 (+0.16%) ▲|NEE76.08+0.46 (+0.61%) ▲|NFLX71.15-0.58 (-0.80%) ▼|NKE35.75-0.24 (-0.67%) ▼|NOW135.62-2.16 (-1.57%) ▼|NVDA225.07+0.49 (+0.22%) ▲|ORCL137.10-2.44 (-1.75%) ▼|PEP128.63+0.48 (+0.37%) ▲|PFE28.67+0.26 (+0.92%) ▲|PG146.23+0.55 (+0.38%) ▲|PLTR189.67-2.92 (-1.52%) ▼|PM190.48-1.02 (-0.53%) ▼|QCOM201.97+7.71 (+3.97%) ▲|RTX189.40+0.79 (+0.42%) ▲|SBUX94.86+1.21 (+1.29%) ▲|SCHW99.03-0.46 (-0.46%) ▼|SO82.88-0.01 (-0.01%) ▼|SPG204.82+0.12 (+0.06%) ▲|T25.38-0.07 (-0.28%) ▼|TMO675.00-3.39 (-0.50%) ▼|TMUS165.43+0.08 (+0.05%) ▲|TSLA372.11-5.83 (-1.54%) ▼|TXN278.07+7.42 (+2.74%) ▲|UBER69.62+0.40 (+0.58%) ▲|UNH376.59+1.58 (+0.42%) ▲|UNP273.79-0.28 (-0.10%) ▼|UPS93.96+1.91 (+2.08%) ▲|USB59.33+0.93 (+1.59%) ▲|V367.38-0.60 (-0.16%) ▼|VZ47.08-0.24 (-0.51%) ▼|WFC82.97+0.79 (+0.96%) ▲|WMT107.98+0.39 (+0.36%) ▲|XOM160.59-1.55 (-0.96%) ▼|
14.9 C
New York
Monday, September 28, 2026

Tag: source

newssourceFORcompanyinformationcontent1releasesmarket

FemiCore (Official Website & Authenticity Notice 2026) – Counterfeit Risks and What Consumers Should Know

FemiCore bladder control capsules 2026 — ingredient information, probiotic strain details, official website verification guidance, and the counterfeit-marketplace red flags consumers are encouraged to be aware of in the women's health supplement category. 
FemiCore bladder control capsules 2026 — ingredient information, probiotic strain details, official website verification guidance, and the counterfeit-marketplace red flags consumers are encouraged to be aware of in the women's health supplement category.

Ripple’s XRP Meets AI Trading: AIXAlpha Launches Free AI Strategy Contracts with Daily Settlement

Join XRP and top assets through AI-driven automated strategies with daily settlement—no manual trading needed. 
Join XRP and top assets through AI-driven automated strategies with daily settlement—no manual trading needed.

/R E P E A T — MEDIA INVITATION – Over 3,000 visitors expected in Montréal to celebrate the 10th anniversary of Dead by...

The world's most profitable horror game, created in Montréal by Behaviour InteractiveMONTREAL, June 12, 2026 /CNW/ - Behaviour Interactive invites members of the media...

As the Lights Fade, Vivid Sydney 2026 Leaves the City Glowing

Images HERESYDNEY, June 13, 2026 /PRNewswire/ -- Off the back of 23 nights of spectacular sights, events and experiences, Vivid Sydney switches off its...

Don’t Pay Full Price for Power: WattCycle’s Prime Day Event Drops Up to 70% Off LiFePO4 Batteries Starting June 15

WattCycle’s June 15-30 sale offers up to 70% off LiFePO4 batteries. Enjoy new arrivals, double points, giveaways & 8% off code: WattCyclePrimeDay.

سيارة «فريلاندر 8» تظهر علناً لأول مرة قبيل إطلاقها الرسمي في أبوظبي

شنغهاي، الصين, June 13, 2026 (GLOBE NEWSWIRE) -- في خطوة تشكل محطة بارزة لقطاع السيارات الكهربائية الفاخرة عالمياً، سجلت سيارة «فريلاندر 8» (FREELANDER 8) ظهورها العلني الأول خلال فعاليات "منتدى أبوظبي للاستثمار - جلسة شنغهاي الخاصة" الذي عُقد في فندق "ذا بنينسولا شنغهاي" في 11 يونيو 2026. ويأتي هذا العرض الأولي في الوقت الذي تستعد فيه العلامة التجارية الفاخرة لإطلاق هويتها رسمياً في منطقة الشرق الأوسط من العاصمة الإماراتية أبوظبي.

CALX EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Calix (CALX) Investors of Securities Class Action Lawsuit Deadline on July 27, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Calix To Contact Him Directly To Discuss Their Options

FREELANDER 8 Makes First Public Appearance Ahead of Official Abu Dhabi Launch

FREELANDER 8 made its first public appearance at the Abu Dhabi Investment Forum held at The Peninsula Shanghai on June 11, 2026.

 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

AIFA 就涉及 HyalRoute Communication Group Limited 的股份收購交易正式作出澄清及反駁

紐約, June 13, 2026 (GLOBE NEWSWIRE) -- All In FutureTech Alliance Inc. (Nasdaq: AIFA)（「公司」或「AIFA」）近日發現，HyalRoute Communication Group Limited（「HyalRoute」）的現任管理團隊以 Dong 女士個人名義，並透過若干柬埔寨媒體及社交媒體渠道，發表或轉發言論，指公司於 2026 年 5 月 22 日有關收購 HyalRoute 控股權益的公告屬「虛假」或「捏造」。

SpaceX perpetual futures become Binance’s No. 2 traded product; Binance captures over 60% market share across CEX and DEX venues

Binance exceeded $5.6 billion in SPCXUSDT trading volume over last 24 hours, with over $9 billion in accumulated trading volume across SpaceX's Pre-IPO and...

AESC and Prevalon Energy Sign 10+ GWh Strategic Supply Agreement to Support Global Energy Storage Growth

SHANGHAI, June 13, 2026 /PRNewswire/ -- AESC, a global leader in high-performance batteries and energy storage systems, and Prevalon Energy, a Mitsubishi Power Americas...

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

BEERSE, BELGIUM, June 13, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the investigational Phase 3 MonumenTAL-3 study.1 The results showed that TALVEY® (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72.0%, and clinically meaningful reduction of up to 53.0% in the risk of death, compared to the standard regimen of daratumumab, pomalidomide, and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma (RRMM).1 Results showed a progression-free survival (PFS) rate of up to 81.3% versus standard of care (51.2%) and an overall survival (OS) rate of up to 89.2% versus standard of care (79.1%) at 24 months.1  

FREELANDER 8 Makes First Public Appearance Ahead of Official Abu Dhabi Launch

FREELANDER 8 made its first public appearance at the Abu Dhabi Investment Forum held at The Peninsula Shanghai on June 11, 2026.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSource

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers